Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3Sarcoma 2Plasma cell 2Dermatologic 2Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Neoplasms by Site 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Bronchiolitis Obliterans Syndrome 1

Interventions

Dexamethasone 393Bortezomib 246Lenalidomide 222Cyclophosphamide 184Melphalan 168Calcium Dobesilate 119Peripheral Blood Stem Cell Transplantation 94fludarabine phosphate 89Thalidomide 82Filgrastim 74carfilzomib 70pomalidomide 68Granulocyte Colony-Stimulating Factor 63Busulfan 63Mycophenolic Acid 61daratumumab 58Whole-Body Irradiation 57ixazomib 54fludarabine 52Tacrolimus 52Prednisone 51Cyclosporine 50Antilymphocyte Serum 35dexamethasone acetate 32plerixafor 30Etoposide 30Methotrexate 29Radiotherapy 28dexamethasone 21-phosphate 27Doxorubicin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × abexinostat × Plasma cell × Clear all
NCT01149668 2013-06-19

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

Pharmacyclics LLC.

Phase 1 Completed
7 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT00562224 2011-09-28

Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients

Pharmacyclics LLC.

Phase 1 Completed
36 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms by Site, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡